Abstract
Interferon (IFN) therapy has been shown to be efficacious in some patients with chronic hepatitis C [1–4]. In responders, normal alanine aminotransferase (ALT) levels and disappearance of hepatitis C virus (HCV) from serum continues for several years and probably permanently after IFN. Such a response is called sustained response, and has been thought to benefit the prognosis of the patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Davis GL, Baklart LA, Schiff ER, et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506
Di Bisceglie AM, Martin P, Kassianides C, et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510
Marcellin P, Boyer N, Giostra E, et al (1991) Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13:393–397
Pagliaro L, Craxi A, Cammaa C, et al (1994) Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19:820–828
Chemello L, Bonetti P, Cavalletto L, et al (1995) Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22:700–706
Shiratori Y, Kato N, Yokosuka O, et al (1997) Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 113:558–566
Desmet VJ, Gerber M, Hoofnagle JH, et al (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520
Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al (1994) Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347–1353
Simmonds P, McOmish F, Yap PL, et al (1993) Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 74:661–668
Urdea MS, Horn T, Fultz TJ, et al (1991) Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 24:197–200
Lau JYN, Davis GL, Kniffen J, et al (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504
Yoshioka K, Higashi Y, Yamada M, et al (1995) Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 15:57–62
Yoshioka K, Kakumu S, Wakita T, et al (1992) Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16:293–299
Hino K, Okuda M, Konishi T, et al (1995) Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci 40:14–20
Orito E, Mizokami M, Suzuki K, et al (1995) Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 46:109–115
Kakumu S, Aiyama T, Okumura A, et al (1997) Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 12:468–472
Sharara AI, Hunt CM, Hamilton JD (1996) Hepatitis C. Ann Intern Med 125:658–668
Kakumu S, Yoshioka K, Tanaka K, et al (1993) Long-term carrier state of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 41:65–70
Lau JY, Mizokami M, Ohno T, et al (1993) Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 342:1208–1209
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Tokyo
About this paper
Cite this paper
Kakumu, S., IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine. (1999). Randomized Controlled Trial of Lymphoblastoid Interferon-α for Chronic Hepatitis C; Early Disappearance of HCV RNA is Essential for Sustained Response. In: Okita, K. (eds) HCV and Related Liver Diseases. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68488-6_7
Download citation
DOI: https://doi.org/10.1007/978-4-431-68488-6_7
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68490-9
Online ISBN: 978-4-431-68488-6
eBook Packages: Springer Book Archive